IL213032A - Pharmaceutical preparations containing crystalline-8-chloro-3-pentyl-3,7-dihydro-1-purine-2,6-dione Tris (hydroxymethyl) aminomethane anhydrate, their combinations, method of preparation and use in the preparation of drugs - Google Patents

Pharmaceutical preparations containing crystalline-8-chloro-3-pentyl-3,7-dihydro-1-purine-2,6-dione Tris (hydroxymethyl) aminomethane anhydrate, their combinations, method of preparation and use in the preparation of drugs

Info

Publication number
IL213032A
IL213032A IL213032A IL21303211A IL213032A IL 213032 A IL213032 A IL 213032A IL 213032 A IL213032 A IL 213032A IL 21303211 A IL21303211 A IL 21303211A IL 213032 A IL213032 A IL 213032A
Authority
IL
Israel
Prior art keywords
preparation
anhydrate
aminomethane
purine
medicaments
Prior art date
Application number
IL213032A
Other languages
English (en)
Hebrew (he)
Other versions
IL213032A0 (en
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of IL213032A0 publication Critical patent/IL213032A0/en
Publication of IL213032A publication Critical patent/IL213032A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL213032A 2008-12-08 2011-05-19 Pharmaceutical preparations containing crystalline-8-chloro-3-pentyl-3,7-dihydro-1-purine-2,6-dione Tris (hydroxymethyl) aminomethane anhydrate, their combinations, method of preparation and use in the preparation of drugs IL213032A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12059608P 2008-12-08 2008-12-08
PCT/US2009/066941 WO2010068581A1 (en) 2008-12-08 2009-12-07 Novel compounds

Publications (2)

Publication Number Publication Date
IL213032A0 IL213032A0 (en) 2011-07-31
IL213032A true IL213032A (en) 2015-02-26

Family

ID=42243044

Family Applications (1)

Application Number Title Priority Date Filing Date
IL213032A IL213032A (en) 2008-12-08 2011-05-19 Pharmaceutical preparations containing crystalline-8-chloro-3-pentyl-3,7-dihydro-1-purine-2,6-dione Tris (hydroxymethyl) aminomethane anhydrate, their combinations, method of preparation and use in the preparation of drugs

Country Status (22)

Country Link
US (3) US9163024B2 (enExample)
EP (1) EP2370440B1 (enExample)
JP (1) JP5666464B2 (enExample)
KR (1) KR101743783B1 (enExample)
CN (1) CN102245606B (enExample)
AU (1) AU2009324811B2 (enExample)
BR (1) BRPI0922134A2 (enExample)
CA (1) CA2746316C (enExample)
CY (1) CY1116032T1 (enExample)
DK (1) DK2370440T3 (enExample)
EA (1) EA020037B1 (enExample)
ES (1) ES2527354T3 (enExample)
HR (1) HRP20150026T1 (enExample)
IL (1) IL213032A (enExample)
MX (1) MX2011006022A (enExample)
PL (1) PL2370440T3 (enExample)
PT (1) PT2370440E (enExample)
RS (1) RS53777B1 (enExample)
SI (1) SI2370440T1 (enExample)
SM (1) SMT201500012B (enExample)
WO (1) WO2010068581A1 (enExample)
ZA (1) ZA201103397B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1781657E (pt) * 2004-02-14 2013-05-23 Glaxosmithkline Ip Dev Ltd Medicamentos com actividade no receptor hm74a
WO2007017262A1 (en) 2005-08-10 2007-02-15 Smithkline Beecham Corporation Xanthine derivatives as selective hm74a agonists
CN104202977A (zh) * 2012-03-22 2014-12-10 转化技术制药有限责任公司 小分子glp1r激动剂的三(羟甲基)氨基甲烷盐及其药物组合物和用途
CN121219290A (zh) 2023-02-27 2025-12-26 珊顿医药科技新加坡公司 化合物8-氯-3-戊基-3,7-二氢-1h-嘌呤-2,6-二酮的晶型及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657327A (en) * 1970-06-01 1972-04-18 Upjohn Co Prostaglandin salts of tris(hydroxymethyl)aminomethane
US4647585A (en) 1984-11-08 1987-03-03 E. R. Squibb & Sons, Inc. Bicycloheptane substituted ethers
JP2003534238A (ja) * 1999-12-15 2003-11-18 スミスクライン・ビーチャム・コーポレイション シス−４−シアノ−４−［３−（シクロペンチルオキシ）−４−メトキシフェニル］シクロヘキサン−１−カルボン酸の塩。
US20030013905A1 (en) 2002-06-10 2003-01-16 Huang Guishu Kris Salts of cis-4-cyano-4[3(cyclopentyloxy)-4-methoxyphenyl]cyclohexane-1-carboxylic acid
PT1781657E (pt) 2004-02-14 2013-05-23 Glaxosmithkline Ip Dev Ltd Medicamentos com actividade no receptor hm74a
US20090209561A1 (en) 2004-10-22 2009-08-20 Richard Jonathan Daniel Hatley Xanthine Derivatives with HM74A Receptor Activity
GB0423568D0 (en) * 2004-10-22 2004-11-24 Smithkline Beecham Corp Novel compounds
WO2007017262A1 (en) 2005-08-10 2007-02-15 Smithkline Beecham Corporation Xanthine derivatives as selective hm74a agonists
GB0516464D0 (en) * 2005-08-10 2005-09-14 Smithkline Beecham Corp Novel compounds

Also Published As

Publication number Publication date
PT2370440E (pt) 2015-01-14
ZA201103397B (en) 2012-01-25
EA020037B1 (ru) 2014-08-29
BRPI0922134A2 (pt) 2015-08-18
CY1116032T1 (el) 2017-01-25
EP2370440A4 (en) 2012-05-30
JP2012511028A (ja) 2012-05-17
MX2011006022A (es) 2011-06-28
EP2370440B1 (en) 2014-11-12
PL2370440T3 (pl) 2015-05-29
RS53777B1 (sr) 2015-06-30
ES2527354T3 (es) 2015-01-22
SMT201500012B (it) 2015-05-03
US20150366870A1 (en) 2015-12-24
AU2009324811A1 (en) 2011-06-23
CN102245606B (zh) 2014-08-20
IL213032A0 (en) 2011-07-31
KR101743783B1 (ko) 2017-06-05
CA2746316A1 (en) 2010-06-17
EA201170783A1 (ru) 2011-12-30
CN102245606A (zh) 2011-11-16
DK2370440T3 (en) 2014-12-08
US9163024B2 (en) 2015-10-20
EP2370440A1 (en) 2011-10-05
CA2746316C (en) 2017-01-03
HRP20150026T1 (hr) 2015-02-13
KR20110097816A (ko) 2011-08-31
US20110251218A1 (en) 2011-10-13
US20170027945A1 (en) 2017-02-02
AU2009324811B2 (en) 2013-01-24
WO2010068581A1 (en) 2010-06-17
SI2370440T1 (sl) 2015-02-27
JP5666464B2 (ja) 2015-02-12

Similar Documents

Publication Publication Date Title
ZA200703277B (en) Novel pyrimidine compounds, process for their preparation and compositions containing them
IL200854A (en) Converted Spiro Compounds, Methods for their Preparation and Pharmaceutical Compositions Containing Them to Delay New Vascular Formation
WO2009059048A3 (en) (+)-opioids and methods of use
ZA200709689B (en) Pyrido[2,3-d]pyrimidines useful as HCV inhibitors, and method for the preparation thereof
GEP20156243B (en) Fused heteroaromatic pyrrolidinones as syk inhibitors
DK1928875T3 (da) 2-Amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-oner, fremgangsmåder til deres fremstilling samt farmaceutiske sammensætninger indeholdende dem
IL198171A0 (en) Dihydropyridine derivatives useful as protein kinase inhibitors
WO2008033851A3 (en) Use of 2-6- (3-amino-piperidin-l-yl) -3-methyl-2, 4-dioxo-3, 4-dihydr0-2h-pyrimidin-1-ylmet hyl-4-fluoro-benzonitrile
ZA201100429B (en) Novel imidazo [1,2-a]pyrimidine derivatives,method for the preparation thereof,use thereof as medicaments,pharmaceutical compositions and novel use in particular as met inhibitors
IL190135A0 (en) Process for the preparation of pyrimidinedione derivatives
WO2006126081A3 (en) Pyridino [2 , 3-b] pyrazinones as pde-5 inhibitors
IL198227A (en) Solid forms containing 4– [9– (Tetrahydro-Puran – 3 – Il) –8– (6,4,2 – Trifluoro-Phenylamino) –9 h– Purin – 2 – Ilamino] –Cyclohexane – 1 – All, process for preparation and preparations And their uses
SI1752443T1 (sl) Nova kristalinična oblika V agomelatina, postopek za njeno pripravo in farmacevtski sestavki, ki jo vsebujejo
IL195915A0 (en) 3-amino -imidazo[1,2-a]pyridine derivatives as sglt inhibitors
WO2010068292A8 (en) Azaindole derivatives as kinase inhibitors
IL205510A0 (en) Benzimidazoledihydrothiadiazinone derivatives as fructose - 1, 6 - bisphosphatase inhibitors, and pharmaceutical compositions comprising same
WO2009007535A3 (fr) Derives de 7 -alkynyl-1.8-naphthyrid0nes, leur preparation et leur application en therapeutique
ZA200904236B (en) 2 substituted-6-heterocyclic pyrimidone derivatives as tau protein kinase 1 inhibitors
IL181827A0 (en) Donepezil salts suitable for the preparation of pharmaceutical compositions
WO2008046919A3 (en) Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors
IL210708A0 (en) Imidazo [1,2-a]pyrimidine derivatives method for the production thereof application thereof as medicaments pharmaceutical compositions and use thereof as met inhibitors
SI2210872T1 (sl) Nova kristalinična oblika iii agomelatina, postopek za njeno pripravo in farmacevtski sestavki, ki jo vsebujejo
EP1938842A4 (en) METHOD FOR PRODUCING A PHARMACEUTICAL COMPOSITION COMPRISING IMPROVED CRASHING CHARACTERISTICS
WO2006005726A3 (en) Heterocyclic compounds
WO2008088779A3 (en) Solid state forms of 5-azacytidine and processes for preparation thereof

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees